Table 1: Inclusion and exclusion criteria.

Inclusion criteria

       Known CNV secondary to AMD or PCV as demonstrated by fluorescein and ICG angiography.

       Prior treatment with at least 4 injections of anti-VEGF agents (bevacizumab or ranibizumab) in the past 6 months and persistent intraretinal or subretinal fluid, or both, on spectral-domain optical coherence tomography during this period.

       Pigment epithelial detachments were included as long as there was associated subretinal fluid or intra retinal oedema.

       BCVA between 35 and 90 ETDRS chart letters.

Exclusion criteria

       Uncontrolled IOP of more than 25 mmHg.

       Current vitreous haemorrhage or inflammation.

       Prior vitrectomy or any intraocular surgery within 2 months of study commencement.

       Anti-VEGF therapy within the previous 30 days; photodynamic therapy within the previous 90 days.

       If the OCT was dry at any time during the 3 months before switching to aflibercept (to allow the inclusion of previously responsive tachyphylactic eyes).

       More than 2 prior photodynamic therapy treatments.

       Presence of significant subretinal fibrosis, tubulation, cystic degeneration or atrophy.

       Significant corneal or lenticular opacities.

       Myocardial infarction, transient ischemic attack, or cerebrovascular accident within the previous 90 days.